Event at a glance

4th Annual Regenerative Medicine and Longevity science Forum

The World Congress brings the world’s most prominent regenerative medicine and longevity scientists together, presenting the new research, responsible drug development, novel therapies and commercialisation to target age-related diseases.

Tuesday 26 April

09:00 Opening Remarks

09:10 Keynote Panel: Regenerative, Rejuvenate or Reprogram?

An in-depth discussion about the applying geroscience to regenerative and longevity research. Investigating how the deeper understanding of ageing biology can progress the next 10 years of stem cells and longevity therapeutics.

Thomas Rando, Co-Founder, Fountain Therapeutics
Eric Verdin, Chief Executive Officer, Buck Institute
Georgina Ellison-Hughes, Professor of Regenerative Muscle Physiology, King's College London
Nir Barzilai, Director, Institute for Aging Research, Albert Einstein College of Medicine

Thomas Rando, Chief Scientific Officer, Fountain Therapeutics 300x   Eric Verdin, Chief Executive Officer, Buck Institute   Georgina Ellison-Hughes   Nir Barzilai, Director, Einstein Institute for Aging Research 300x

10:00 Keynote Panel: The COVID-19 Impact

COVID-19, the disease caused by the coronavirus Sars-CoV-2, is most prevalent in older adults, causes more severe symptoms in this population and over 90% of deaths are in the over 65 year olds.

Gain insights into how COVID-19 has impacted on social issues and research data on ageing science, including describing how an aged immune system contributes to this increased morbidity and mortality in older adults and also discuss research into the long term consequences for immunity and overall health in COVID-19 survivors. Then discuss how any lesson learnt can be applied to improve healthspan going forward.

James Kirkland, Director of the Robert and Arlene Kogod Centre on Aging, Mayo Clinic
Janet Lord, Director of the Institute of Inflammation and Ageing, University of Birmingham 

James Kirkland, Professor of Physiology & Medicine, Mayo Clinic 300x   Janet Lord, Director, Institute of Inflammation and Ageing, Birmingham University 300x

10:00 Morning Break

Longevity Therapeutics

Advancing mechanistic understanding

11:20 Presentation: The role of immune ageing for cellular senescence applications

Understanding the importance of changes in immunity and any associated changes with time critical to the ageing process and subsequent therapeutic targets.

Immune aging can be monitored by the immune responses which change depending on diet.

In this presentation we will discuss the latest parameters and mechanisms that can induce such change.

Including exploring the interlinking role cellular metabolites, for example NAD+ plays in aging, neurodegeneration, and metabolism.

Also, a deep dive into how to regulate senescence and chronic inflammation with nutrition.

Eric Verdin, Chief Executive Officer, Buck Institute

Eric Verdin, Chief Executive Officer, Buck Institute

11:50 Presentation: Revisiting enzymatic approaches, elongation of telomeres for therapeutic use to target fibrosis diseases

Pulmonary fibrosis is an age related condition which globally affects over 120,000 people and due to an ageing population, the number new cases is estimated to grow by 50,000 in the next five years.

Understanding ageing mechanisms associated with the fibrotic disease will allow for more targeted and in turn and efficacious treatment. Explore the pathologies and data around telomeres to produce a gene therapy to treat pulmonary fibrosis.

Maria Blasco, Group Leader and Founder, CNIO and Telomere Therapeutics

Maria Blasco

12:10 Panel: Applying mitochondria mechanistic learnings to successfully target NASH pathways and AMD indications

Hear about the latest updates on molecular mechanisms around mitochondrial dysfunction to develop therapeutic peptides. Gain insights in early clinical developments on targeting metabolic and macular degeneration diseases

Reenie McCarthy, Chief Executive Officer, Stealth Bio Joseph Sarret, Chief Executive Officer and Director, CohBar

Reenie McCarthy, CEO, Stealth BioTherapeutics 300x   Joseph Sarret


Regenerative Medicine Track

Innovative technologies and mechanistic understanding

11:20 Presentation: Understanding the role of cell senescence and homeostasis in targeting cardiac regeneration

Mammalian ageing is defined as a gradual loss of the capacity to maintain tissue homeostasis or to repair tissues after injury/stress. The adult heart is considered a post-mitotic organ, having a low cardiomyocyte turnover rate over the course of human lifespan, which decreases further with ageing.

Like other tissues and organs senescent cells accumulate in the heart with ageing and in chronic disease, contributing to pathophysiology and deterioration. Regulation of cell senescence will impact the efficacy of regenerative therapies, especially if the majority of patients in need of it are of advanced age as occurs with heart disease and failure.

Targeting cell senescence using senolytics can rejuvenate the aged hearts regenerative capacity.

Georgina Ellison-Hughes, Professor of Regenerative Muscle Physiology, King's College London

Georgina Ellison-Hughes

11:50 Presentation: Exploring the novel molecular mechanisms within the brain targeting Alzheimer’s disease that can be translated to clinic

Examine how the relationship between cellular senescence and the chronic neurodegenerative diseases, including the mechanism around tau toxicities impacting cellular senescence in the brain.

Miranda Orr, Assistant Professor, Gerontology and Geriatric Medicine, Wake Forest School of Medicine

Miranda Orr

12:10 Presentation: Ovarian ageing, reproductive longevity health and rejuvenation

Ovarian aging is perhaps the most promising but overlooked area in ageing science. It has the potential to provide insights into how the rest of the body ages. Discuss how the fundamental advancements within female reproductive ageing and how research can lead to promising fertility, perimenopause, and menopause treatments. Also, the potential of developing therapies to target ovarian indications allows researchers to target early aged human models.

Jennifer Garrison, Associate Director, Buck-USC Biology of Aging. Bucks Institute and Founder & Director, Global Consortium for Reproductive Longevity & Equality

Jennifer Garrison

12:40 Lunch


14:00 Panel: Targeting Ageing the Beyond Therapeutics

How is important is diet, sleep, stress, exercise, and genetics for ageing and treating chronic diseases approach? Is a low caloric diet essential? Explore recent findings around the data the impact stress and sleep have on the biological age.

Greg Bailey, Chief Executive Officer, Juvenescence Ltd Grace McNamara, Chief Executive Officer, Exi
Kate Bache, Co-Founder and CEO, Health & Her

Greg Bailey, CEO, Juvenescence 200x   Grace McNamara, CEO, Exi 300x   Kate Bache, Co-Founder & Managing Director, Health & Her 300x

14:40 Presentation: The right and practical data Ageing

Utilising Multi-omics, Big Data, Deep Learning, Machine Learning and AI to reduce the complexity of ageing as an indication. Discover the partialities and opportunities of using system biology to target HIF-H inhibitor ad APJ Agonist to treat muscle ageing.

Kristen Fortney, Co-founder and Chief Executive Officer, BioAge

Kristen Fortney

15:00 Panel: De-risking ageing drug development

The right early-stage data is crucial to move beyond the concept stage and secure investment.

Review the tools that can accurately assess how well lead compounds slow down the process ageing within early-stage research. And identify the key data for longevity drug discovery and addressing the hurdles to obtain the data.

David Weinkove, Co-Founder & CEO, Magnitude Biosciences
Patrick Burgermesiter, Partner, Kizoo Technology Capital
Joan Mannick, Head of R&D at Life Biosciences

David Weinkove   Patrick Burgermesiter   Joan Mannick, CMO, resTORbio 300x-1

14:00 Fireside chat: Building robust and scalable manufacturing and supply chain network for age-related cell and gene therapies

Julie Allickson, Director, Mayo Clinic Center for Regenerative Medicine

Julie Allickson,

14:50 Panel: Beyond the therapeutic - The consumer and OTC regenerative medicine opportunity

Discussing the market opportunities for rejuvenation applications that can be utilised direct-to-consumer such as wound management, skin care and dental care.

Alan Goldstein, Managing Director of P&G Ventures, Proctor and Gamble
Saranya Wylves, Assistant Professor of regenerative medicine and dermatologist, Mayo Clinic School of Medicine

Alan Goldstein, Managing Director of P&G Ventures, Proctor and Gamble   Saranya Wylves


15:40 Afternoon Break

16:10 Roundtables

  • Incorporating a systemic approach and ageing biomarkers in clinical trials
  • Reimbursement strategies for regenerative products
  • Navigating cold chain supply chain and logistics Incorporating cellular senescence and stem cells
  • Intellectual Property and legal considerations
  • Delivery approaches – exosomes vs LNP vs Viral vectors
  • Cell and gene therapy clinical considerations for rare diseases

17:30 Close of day 1 and Rejuvenate reception



Wednesday 27 April


09:00 Keynote Panel: Investment landscape within Regenerative medicine and Longevity Therapeutics

Removing the taboo of longevity and regenerative medicine within traditional biotech investment dynamics. Understand how the landscape is changing with new investment providers and deep dive into their due diligence process.

Alexandra Bause, Investor Director, Apollo Ventures
Ronjon Nag, Managing Director and Founder, R42 Group

Alexandra Bause, Co-Founder, Investment Director & Head of VentureLabs, Apollo Health Ventures   Ronjon Nag, Managing Director & Founder, R42 Institute 300x

09:50 Keynote Panel: Translating and commercialising regenerative medicine and ageing science therapeutics

Assessing the route to market options by developing biologic or medical device designation. How do they differ in IP potential and market access parameters (pricing and reimbursement strategies)? How large a role is buy from big Pharma critical for commercialisation for regenerative products over companies establishing themselves as ‘big’ biopharma. Discussing how the advancements of regenerative medicine to translate real world interventions can be applied to longevity therapeutics and gain more interest from larger player and payers.

Joshua Hare, Co-Founder, Chief Science Officer and Chairman, Longeveron
Tea Shavlakadze, Director of Aging/Age-Related disorders, Regeneron Pharmaceuticals
Natalia Novac
, Director Emerging Technology & Innovation, Eli Lilly

Joshua Hare   Tea Shavlakadze   Natalia Novac, Senior Director, Venture Science,  Lilly New Ventures, Corporate Business Development, Eli Lilly and Company

10:35 Morning Break

11:00 Panel: Commercialising skin with hard data

Skin, the largest organ, has seen commercial success in rejuvenation, particularly in Aesthetics and Cosmetics. But robust clinical data for dermatology is scrutinised. How much is the consumer is driving the market, is there enough data to back up the demand clinically? And what can be done to address the gaps? Hear about the innovative companies and technology the cosmetic and consumer market leaders are reviewing to back robust clinically proven research.

Betsy Bluestone, Head of Discovery - P&G Ventures, Procter & Gamble
Sibylle Jager, Scientific Directorate Manager, L’Oréal
Stephanie Manson-Brown, Head of Clinical Development, VP Allergan Aesthetics R&D, AbbVie

Betsy Bluestone   Sibylle Jager, Scientific Directorate Manager, LOREAL   Stephanie Manson Brown, Head of Clinical Development, Allergan 300x


Longevity Therapeutics

Clinical Insights

11:50 Presentation: Macular degenerative clinical development via targeting BCL pathway

Explore ocular cell biology around the senescent triggers in across the BCL-xL pathway. Assess how the applied developed lead compound through the clinic. Hear the Phase II/III patient results.

Jamie Danaberg, Chief Medical Officer, UNITY Biotechnology

Jamie Danaberg, Chief Medical Officer, UNITY Biotechnology


Regenerative Medicine Track

Clinical Insights

11:50 Presentation: Phase III clinical update of targeting muscle regeneration with PLX-PAD

Learn the clinical design process for the PLX-PAD to induce muscle regeneration after hip fracture surgery. Hear the up-to-date phase III clinical data from this cell therapy approach.

Nitsan Halevy, Chief Medical Officer, Pluristem

Nitsan Halevy

12:15 Lunch


13:30 Dermatology pre-clinical development via modulation of RNA splicing

  • Regulated mRNA processing is achieved by the combinatorial action of splicing factors; proteins which activate or inhibit splice site choice.
  • Splicing factor expression declines during ageing because of constitutive and unresolved cellular signalling, with is a provocation towards cellular senescence.
  • Treatment of senescent cells with small molecules or targeted oligonucleotide interventions designed to restore splicing factor expression can ameliorate multiple features of senescence in human primary skin cells.
  • Dysregulation of mRNA splicing may represent a new (and druggable) driver of cellular ageing, which can be targeted to treat the causes, rather than the consequences, of cellular ageing.

Lorna Harries, Chief Scientific Officer, Senisca

Lorna Harries, Professor, University of Exeter 300x-1

14:00 Harnessing endogenous immune biology to ablate pathogenic senescent cells and treat disease

  • Identifying the endogenous immune mechanism for clearing senescent cells
  • Therapeutically harnessing the immune system to remove senescent cells in a disease state
  • Achieving therapeutically relevant endpoints and durable effects
  • A paradigm shift for systemically treating age related multi-morbidities

Robin Mansukhani, CEO, Deciduous Therapeutics

Robin Mansukhani, CEO, Deciduous Therapeutics

13:30 Presentation: Preclinical data of comprehensive tissue types to target the age process in cardiovascular and neurodegenerative disease

Examine the in vivo and preclinical data from 36 tissue types associated with cardiovascular and neurology indications. Gain nights into how the preclinical results are being translated in the clinical trial status.

Tea Shavlakadze, Director of Aging/Age-Related disorders, Regeneron Pharmaceuticals

Tea Shavlakadze, Director of AgingAge-Related disorders, Regeneron Pharmaceuticals

14:00 Presentation: Advancing aging frailty through the clinic with ageing clinical endpoints

Hear the latest data in the advanced 150 patient enrolled trial targeting ageing frailty. Discover ageing biomarkers and clinical endpoints used for an aged, focused indication. Explore whether the phase II trial with Lomecel-B is positive is reducing inflammation and improving physical function.

Joshua Hare, Co-Founder, Chief Science Officer and Chairman, Longeveron

Joshua Hare

14:30 Afternoon Break

15:00 Panel: Tackling Immunogenicity in gene therapy, cell therapy and organ transplantation

Discussing the triggers off allogenic graft rejection, the mechanistic understanding of immunogenicity and importance when developing cell and gene therapy.

Stefan Tullius, Professor of Surgery, Transplant Surgery, Harvard Medical School
Michael Hufford, Co-Founder and CEO, Lygenesis

Stefan Tullius   Michael Hufford, Co-Founder and CEO, Lygenesis

15:50 Panel: Longevity therapeutic clinical trial review and forward thinking

Deep dive into the pros and cons of the p53 and mTOR longevity related trials to assess how to set future trials for success. Assess the decision process around picking the right indication for drug development. Examine the clinical design tools (biomarker, endpoints and analytical tools.)

Joan Mannick, Head of R&D at Life Biosciences
Nathaniel David, Co-Founder, UNITY Biotechnology

Joan Mannick, CMO, resTORbio 300x-1   Nathaniel David, President, Unity Biotechnology, Inc. 300x

16:40 Roundtables

  • How to achieve consensus around the biology of ageing
  • The right indication for drug development
  • How to translate Plasma and generic drugs as commercial therapeutic tools for ageing
  • Delivery approaches – exosomes vs LNP vs Viral vectors
  • Novel biomaterials, bioelectronics and constructs for regenerative medicine

17:20 Closing Remarks

17:30 Congress Closes